Frederic Jaisser

List of Publications by Year
in descending order

160 papers	8,583 citations	34105 52 h-index	54911 84 g-index
166 all docs	166 docs citations	166 times ranked	8718 citing authors

#	Article	IF	Citations
1	Role of the vascular endothelial sodium channel activation in the genesis of pathologically increased cardiovascular stiffness. Cardiovascular Research, 2022, 118, 130-140.	3.8	29
2	Mineralocorticoid receptor antagonists in diabetic kidney disease â€" mechanistic and therapeutic effects. Nature Reviews Nephrology, 2022, 18, 56-70.	9.6	87
3	The mineralocorticoid receptor in chronic kidney disease. British Journal of Pharmacology, 2022, 179, 3152-3164.	5.4	13
4	Neutrophil Gelatinase-Associated Lipocalin From Macrophages Plays a Critical Role in Renal Fibrosis Via the CCL5 (Chemokine Ligand 5)-Th2 Cells-IL4 (Interleukin 4) Pathway. Hypertension, 2022, 79, 352-364.	2.7	13
5	Chronic Systemic Dexamethasone Regulates the Mineralocorticoid/Glucocorticoid Pathways Balance in Rat Ocular Tissues. International Journal of Molecular Sciences, 2022, 23, 1278.	4.1	8
6	Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases. Annual Review of Physiology, 2022, 84, 585-610.	13.1	31
7	Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice. Frontiers in Physiology, 2022, 13, 859812.	2.8	9
8	Nonepithelial mineralocorticoid receptor activation as a determinant of kidney disease. Kidney International Supplements, 2022, 12, 12-18.	14.2	16
9	Endothelial sodium channel activation mediates DOCA-salt-induced endothelial cell and arterial stiffening. Metabolism: Clinical and Experimental, 2022, 130, 155165.	3.4	7
10	Sex-Related Signaling of Aldosterone/Mineralocorticoid Receptor Pathway in Calcific Aortic Stenosis. Hypertension, 2022, 79, 1724-1737.	2.7	8
11	Biglycan Is a Novel Mineralocorticoid Receptor Target Involved in Aldosterone/Salt-Induced Glomerular Injury. International Journal of Molecular Sciences, 2022, 23, 6680.	4.1	2
12	The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease. Clinical Science, 2022, 136, 1005-1017.	4.3	5
13	The Mineralocorticoid Receptor Antagonist Eplerenone Suppresses Interstitial Fibrosis in Subcutaneous Adipose Tissue in Patients With Type 2 Diabetes. Diabetes, 2021, 70, 196-203.	0.6	6
14	Antifibrotic effect of novel neutrophil gelatinase-associated lipocalin inhibitors in cardiac and renal disease models. Scientific Reports, 2021, 11, 2591.	3.3	11
15	Nanostructured Dense Collagenâ€Polyester Composite Hydrogels as Amphiphilic Platforms for Drug Delivery. Advanced Science, 2021, 8, 2004213.	11.2	40
16	Mineralocorticoid receptor blockade with finerenone improves heart function and exercise capacity in ovariectomized mice. ESC Heart Failure, 2021, 8, 1933-1943.	3.1	17
17	Adipocyte-Mineralocorticoid Receptor Alters Mitochondrial Quality Control Leading to Mitochondrial Dysfunction and Senescence of Visceral Adipose Tissue. International Journal of Molecular Sciences, 2021, 22, 2881.	4.1	8
18	The Non-Steroidal Mineralocorticoid Receptor Antagonist KBP-5074 Limits Albuminuria and has Improved Therapeutic Index Compared With Eplerenone in a Rat Model With Mineralocorticoid-Induced Renal Injury. Frontiers in Pharmacology, 2021, 12, 604928.	3.5	13

#	ARTICLE	IF	CITATIONS
19	Beneficial Effects of Mineralocorticoid Receptor Pathway Blockade against Endothelial Inflammation Induced by SARS-CoV-2 Spike Protein. Biomedicines, 2021, 9, 639.	3.2	20
20	Editorial: Kidney and Distant Organ Crosstalk in Health and Disease. Frontiers in Physiology, 2021, 12, 712535.	2.8	1
21	MR (Mineralocorticoid Receptor) in Endothelial Cells: A Major Contributor in Pulmonary Arterial Hypertension Remodeling. Hypertension, 2021, 78, 466-468.	2.7	2
22	Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics. Expert Opinion on Investigational Drugs, 2021, 30, 1141-1157.	4.1	26
23	Letter to the Editor From Behar-Cohen et al.: â€œThe Cortisol Response of Male and Female Choroidal Endothelial Cells: Implications for Central Serous Chorioretinopathyâ€• Journal of Clinical Endocrinology and Metabolism, 2021, , .	3.6	1
24	Vascular and inflammatory mineralocorticoid receptors in kidney disease. Acta Physiologica, 2020, 228, e13390.	3.8	7
25	Cutaneous Wound Healing in Diabetic Mice Is Improved by Topical Mineralocorticoid Receptor Blockade. Journal of Investigative Dermatology, 2020, 140, 223-234.e7.	0.7	40
26	Beneficial Effects of Mineralocorticoid Receptor Antagonism on Myocardial Fibrosis in an Experimental Model of the Myxomatous Degeneration of the Mitral Valve. International Journal of Molecular Sciences, 2020, 21, 5372.	4.1	10
27	A New Role for the Aldosterone/Mineralocorticoid Receptor Pathway in the Development of Mitral Valve Prolapse. Circulation Research, 2020, 127, e80-e93.	4.5	17
28	Endothelial sodium channel activation promotes cardiac stiffness and diastolic dysfunction in Western diet fed female mice. Metabolism: Clinical and Experimental, 2020, 109, 154223.	3.4	13
29	Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes, Obesity and Metabolism, 2020, 22, 16-31.	4.4	91
30	Western diet induces renal artery endothelial stiffening that is dependent on the epithelial Na⁺ channel. American Journal of Physiology - Renal Physiology, 2020, 318, F1220-F1228.	2.7	13
31	Effect of acute and chronic aldosterone exposure on the retinal pigment epithelium-choroid complex in rodents. Experimental Eye Research, 2019, 187, 107747.	2.6	25
32	Epithelial sodium channels in endothelial cells mediate diet-induced endothelium stiffness and impaired vascular relaxation in obese female mice. Metabolism: Clinical and Experimental, 2019, 99, 57-66.	3.4	40
33	The Absence of Endothelial Sodium Channel Î± (Î±ENaC) Reduces Renal Ischemia/Reperfusion Injury. International Journal of Molecular Sciences, 2019, 20, 3132.	4.1	17
34	Myocardial Injury After Ischemia/Reperfusion Is Attenuated By Pharmacological Galectin-3 Inhibition. Scientific Reports, 2019, 9, 9607.	3.3	35
35	Vascular mineralocorticoid receptor activation and disease. Experimental Eye Research, 2019, 188, 107796.	2.6	15
36	Mineralocorticoid receptor antagonism limits experimental choroidal neovascularization and structural changes associated with neovascular age-related macular degeneration. Nature Communications, 2019, 10, 369.	12.8	47

#	Article	IF	Citations
37	Emerging therapeutic strategies for transplantation-induced acute kidney injury: protecting the organelles and the vascular bed. Expert Opinion on Therapeutic Targets, 2019, 23, 495-509.	3.4	11
38	Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis. Kidney International, 2019, 96, 302-319.	5.2	145
39	Dendritic cells are crucial for cardiovascular remodeling and modulate neutrophil gelatinase-associated lipocalin expression upon mineralocorticoid receptor activation. Journal of Hypertension, 2019, 37, 1482-1492.	0.5	23
40	CT-1 (Cardiotrophin-1)-Gal-3 (Galectin-3) Axis in Cardiac Fibrosis and Inflammation. Hypertension, 2019, 73, 602-611.	2.7	78
41	MR (Mineralocorticoid Receptor) Induces Adipose Tissue Senescence and Mitochondrial Dysfunction Leading to Vascular Dysfunction in Obesity. Hypertension, 2019, 73, 458-468.	2.7	46
42	Cardiac expression of neutrophil gelatinaseâ€associated lipocalin in a model of cancer cachexiaâ€induced cardiomyopathy. ESC Heart Failure, 2019, 6, 89-97.	3.1	14
43	Mineralocorticoid receptor antagonists in kidney transplantation: time to consider?. Nephrology Dialysis Transplantation, 2018, 33, 2080-2091.	0.7	8
44	Vascular dysfunction in obese diabetic db/db mice involves the interplay between aldosterone/mineralocorticoid receptor and Rho kinase signaling. Scientific Reports, 2018, 8, 2952.	3.3	32
45	Neutrophil Gelatinase-Associated Lipocalin from immune cells is mandatory for aldosterone-induced cardiac remodeling and inflammation. Journal of Molecular and Cellular Cardiology, 2018, 115, 32-38.	1.9	47
46	Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12. Scientific Reports, 2018, 8, 6801.	3.3	22
47	The myeloid mineralocorticoid receptor controlsÂinflammatory and fibrotic responses afterÂrenal injury via macrophage interleukin-4 receptor signaling. Kidney International, 2018, 93, 1344-1355.	5.2	109
48	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	3.1	21
49	EPURE Transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial. Trials, 2018, 19, 595.	1.6	10
50	Mineralocorticoid Receptor and Cardiovascular Disease. American Journal of Hypertension, 2018, 31, 1165-1174.	2.0	80
51	New roles of aldosterone and mineralocorticoid receptors in cardiovascular disease: translational and sex-specific effects. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H989-H999.	3.2	23
52	The Deletion of Endothelial Sodium Channel Î± (Î±ENaC) Impairs Endothelium-Dependent Vasodilation and Endothelial Barrier Integrity in Endotoxemia in Vivo. Frontiers in Pharmacology, 2018, 9, 178.	3.5	29
53	Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice. Journal of Molecular and Cellular Cardiology, 2018, 121, 124-133.	1.9	32
54	Epithelial Sodium Channel in Aldosterone-Induced Endothelium Stiffness and Aortic Dysfunction. Hypertension, 2018, 72, 731-738.	2.7	61

#	Article	IF	Citations
55	More than a simple biomarker: the role of NGAL in cardiovascular and renal diseases. Clinical Science, 2018, 132, 909-923.	4.3	98
56	Minor role of mature adipocyte mineralocorticoid receptor in high-fat diet-induced obesity. Journal of Endocrinology, 2018, 239, 229-240.	2.6	13
57	Shortâ€•and longâ€term administration of the nonâ€steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndromeâ€related cardioâ€renal dysfunction. Diabetes, Obesity and Metabolism, 2018, 20, 2399-2407.	4.4	36
58	Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS ONE, 2018, 13, e0193380.	2.5	46
59	Benefit of Mineralocorticoid Receptor Antagonism in AKI: Role of Vascular Smooth Muscle Rac1. Journal of the American Society of Nephrology: JASN, 2017, 28, 1216-1226.	6.1	68
60	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	7.1	280
61	Aldosterone and Vascular Mineralocorticoid Receptors in Murine Endotoxic and Human Septic Shock*. Critical Care Medicine, 2017, 45, e954-e962.	0.9	30
62	Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injuryâ€"Mediated Chronic Kidney Disease. Hypertension, 2017, 69, 870-878.	2.7	92
63	Aldosterone Target NGAL (Neutrophil Gelatinaseâ€"Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFÎºB Pathway. Hypertension, 2017, 70, 1148-1156.	2.7	67
64	Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts. Scientific Reports, 2017, 7, 12192.	3.3	29
65	Differential proteomics reveals S100-A11 as a key factor in aldosterone-induced collagen expression in human cardiac fibroblasts. Journal of Proteomics, 2017, 166, 93-100.	2.4	9
66	11Î²-HSD2 SUMOylation Modulates Cortisol-Induced Mineralocorticoid Receptor Nuclear Translocation Independently of Effects on Transactivation. Endocrinology, 2017, 158, 4047-4063.	2.8	14
67	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. Journal of Translational Medicine, 2017, 15, 202.	4.4	33
68	The endothelial Î±ENaC contributes to vascular endothelial function in vivo. PLoS ONE, 2017, 12, e0185319.	2.5	47
69	Safety of Eplerenone for Kidney-Transplant Recipients with Impaired Renal Function and Receiving Cyclosporine A. PLoS ONE, 2016, 11, e0153635.	2.5	19
70	Adipocyte-Specific Mineralocorticoid Receptor Overexpression in Mice Is Associated With Metabolic Syndrome and Vascular Dysfunction: Role of Redox-Sensitive PKG-1 and Rho Kinase. Diabetes, 2016, 65, 2392-2403.	0.6	46
71	Histone Deacetylase 6â€"Controlled Hsp90 Acetylation Significantly Alters Mineralocorticoid Receptor Subcellular Dynamics But Not its Transcriptional Activity. Endocrinology, 2016, 157, 2515-2532.	2.8	22
72	Mineralocorticoid receptor antagonists: a patent evaluation of US20150284376A1. Expert Opinion on Therapeutic Patents, 2016, 26, 1111-1114.	5.0	1

#	Article	IF	Citations
73	Cardiomyocyte-specific overexpression of oestrogen receptor Î² improves survival and cardiac function after myocardial infarction in female and male mice. Clinical Science, 2016, 130, 365-376.	4.3	44
74	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handbook of Experimental Pharmacology, 2016, 243, 271-305.	1.8	102
75	Mineralocorticoid Receptor Antagonism: A Promising Therapeutic Approach to Treat Ischemic AKI. Nephron, 2016, 134, 10-13.	1.8	7
76	Re-Epithelialization of Pathological Cutaneous Wounds Is Improved by Local Mineralocorticoid Receptor Antagonism. Journal of Investigative Dermatology, 2016, 136, 2080-2089.	0.7	31
77	Vascular Smooth Muscle Mineralocorticoid Receptor Contributes to Coronary and Left Ventricular Dysfunction After Myocardial Infarction. Hypertension, 2016, 67, 717-723.	2.7	69
78	Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration. Kidney International, 2016, 89, 354-362.	5.2	52
79	Sulfenic Acid Modification of Endothelin B Receptor is Responsible for the Benefit of a Nonsteroidal Mineralocorticoid Receptor Antagonist in Renal Ischemia. Journal of the American Society of Nephrology: JASN, 2016, 27, 398-404.	6.1	50
80	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	7.1	109
81	Mild ischemic Injury Leads to Long-Term Alterations in the Kidney: Amelioration by Spironolactone Administration. International Journal of Biological Sciences, 2015, 11, 892-900.	6.4	34
82	Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Progress in Retinal and Eye Research, 2015, 48, 82-118.	15.5	712
83	Neutrophil Gelatinaseâ€"Associated Lipocalin, a Novel Mineralocorticoid Biotarget, Mediates Vascular Profibrotic Effects of Mineralocorticoids. Hypertension, 2015, 66, 158-166.	2.7	75
84	Mineralocorticoid Receptor Activation and Mineralocorticoid Receptor Antagonist Treatment in Cardiac and Renal Diseases. Hypertension, 2015, 65, 257-263.	2.7	169
85	Role of smooth muscle cell mineralocorticoid receptor in vascular tone. Pflugers Archiv European Journal of Physiology, 2015, 467, 1643-1650.	2.8	20
86	Galectin-3 Blockade Inhibits Cardiac Inflammation and Fibrosis in Experimental Hyperaldosteronism and Hypertension. Hypertension, 2015, 66, 767-775.	2.7	129
87	Adipocyte Mineralocorticoid Receptor Activation Leads to Metabolic Syndrome and Induction of Prostaglandin D2 Synthase. Hypertension, 2015, 66, 149-157.	2.7	91
88	Interleukin-33/ST2 system attenuates aldosterone-induced adipogenesis and inflammation. Molecular and Cellular Endocrinology, 2015, 411, 20-27.	3.2	26
89	Vascular mineralocorticoid receptor and blood pressure regulation. Current Opinion in Pharmacology, 2015, 21, 138-144.	3.5	19
90	Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin. Journal of Investigative Dermatology, 2015, 135, 1781-1789.	0.7	40

#	Article	IF	Citations
91	Aldosterone Promotes Cardiac Endothelial Cell Proliferation In Vivo. Journal of the American Heart Association, 2015, 4, e001266.	3.7	15
92	Endothelial Mineralocorticoid Receptors Differentially Contribute to Coronary and Mesenteric Vascular Function Without Modulating Blood Pressure. Hypertension, 2015, 66, 988-997.	2.7	84
93	Simultaneous Characterization of Metabolic, Cardiac, Vascular and Renal Phenotypes of Lean and Obese SHHF Rats. PLoS ONE, 2014, 9, e96452.	2.5	11
94	Cardiomyocyte-specific Estrogen Receptor Alpha Increases Angiogenesis,Lymphangiogenesis and Reduces Fibrosis in the Female Mouse Heart Post-Myocardial Infarction. Journal of Cell Science & Therapy, 2014, 05, 153.	0.3	51
95	Aldosterone and Vascular Mineralocorticoid Receptors. Hypertension, 2014, 63, 632-637.	2.7	33
96	Mineralocorticoid receptor modulators: a patent review (2007 â€“ 2012). Expert Opinion on Therapeutic Patents, 2014, 24, 177-183.	5.0	12
97	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	2.2	167
98	Circulating Osteoglycin and NGAL/MMP9 Complex Concentrations Predict 1-Year Major Adverse Cardiovascular Events After Coronary Angiography. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1078-1084.	2.4	53
99	Endothelial Cell Mineralocorticoid Receptors. Hypertension, 2014, 63, 915-917.	2.7	17
100	Smooth Muscle Cell Mineralocorticoid Receptors Are Mandatory for Aldosteroneâ€“Salt to Induce Vascular Stiffness. Hypertension, 2014, 63, 520-526.	2.7	97
101	Endothelial mineralocorticoid receptor activation enhances endothelial protein C receptor and decreases vascular thrombosis in mice. FASEB Journal, 2014, 28, 2062-2072.	0.5	25
102	The epithelial Na+ channel. Current Opinion in Nephrology and Hypertension, 2014, 23, 143-148.	2.0	27
103	Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells. Nature Reviews Nephrology, 2014, 10, 146-157.	9.6	97
104	Mineralocorticoid receptor and cardiac arrhythmia. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 910-915.	1.9	18
105	Aldosterone-Specific Activation of Cardiomyocyte Mineralocorticoid Receptor In Vivo. Hypertension, 2013, 61, 361-367.	2.7	70
106	Epithelial Sodium Channel Stiffens the Vascular Endothelium In Vitro and in Liddle Mice. Hypertension, 2013, 61, 1053-1059.	2.7	96
107	The Diuretic Torasemide Does Not Prevent Aldosterone-Mediated Mineralocorticoid Receptor Activation in Cardiomyocytes. PLoS ONE, 2013, 8, e73737.	2.5	32
108	The Epidermal Growth Factor Receptor Is Involved in Angiotensin II But Not Aldosterone/Salt-Induced Cardiac Remodelling. PLoS ONE, 2012, 7, e30156.	2.5	15

#	Article	IF	Citations
109	Neutrophil Gelatinase-Associated Lipocalin Is a Novel Mineralocorticoid Target in the Cardiovascular System. Hypertension, 2012, 59, 966-972.	2.7	73
110	Extrarenal effects of aldosterone. Current Opinion in Nephrology and Hypertension, 2012, 21, 147-156.	2.0	86
111	369 VASCULAR EFECTS OF ALDOSTERONE. Journal of Hypertension, 2012, 30, e108.	0.5	0
112	Novel Transgenic Mice for Inducible Gene Overexpression in Pancreatic Cells Define Glucocorticoid Receptor-Mediated Regulations of Beta Cells. PLoS ONE, 2012, 7, e30210.	2.5	25
113	Cardiomyopathy and Response to Enzyme Replacement Therapy in a Male Mouse Model for Fabry Disease. PLoS ONE, 2012, 7, e33743.	2.5	16
114	Targeting the aldosterone pathway in cardiovascular disease. Fundamental and Clinical Pharmacology, 2012, 26, 135-145.	1.9	6
115	Aldosterone, mineralocorticoid receptor, and heart failure. Molecular and Cellular Endocrinology, 2012, 350, 266-272.	3.2	100
116	Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. Journal of Clinical Investigation, 2012, 122, 2672-2679.	8.2	316
117	The Aldosterone-Mineralocorticoid Receptor Pathway Exerts Anti-Inflammatory Effects in Endotoxin-Induced Uveitis. PLoS ONE, 2012, 7, e49036.	2.5	30
118	Aldosterone and the mineralocorticoid receptor. European Heart Journal Supplements, 2011, 13, B4-B9.	0.1	9
119	The Mineralocorticoid Receptor in Heart. Hypertension, 2011, 57, 679-680.	2.7	20
120	Differential Regulations of AQP4 and Kir4.1 by Triamcinolone Acetonide and Dexamethasone in the Healthy and Inflamed Retina. , 2011, 52, 6340.		63
121	Epidermal Growth Factor Receptor Mediates the Vascular Dysfunction But Not the Remodeling Induced by Aldosterone/Salt. Hypertension, 2011, 57, 238-244.	2.7	39
122	Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease. Kidney International, 2011, 79, 1051-1060.	5.2	107
123	Coronary endothelial dysfunction after cardiomyocyte-specific mineralocorticoid receptor overexpression. American Journal of Physiology - Heart and Circulatory Physiology, 2011, 300, H2035-H2043.	3.2	46
124	Tamoxifen administration routes and dosage for inducible Cre-mediated gene disruption in mouse hearts. Transgenic Research, 2010, 19, 715-725.	2.4	60
125	The mineralocorticoid receptor as a novel player in skin biology: beyond the renal horizon?. Experimental Dermatology, 2010, 19, 100-107.	2.9	46
126	The endothelial mineralocorticoid receptor regulates vasoconstrictor tone and blood pressure. FASEB Journal, 2010, 24, 2454-2463.	0.5	135

#	Article	IF	Citations
127	The Mineralocorticoid Receptor Is a Constitutive Nuclear Factor in Cardiomyocytes due to Hyperactive Nuclear Localization Signals. Endocrinology, 2010, 151, 3888-3899.	2.8	32
128	Molecular Signature of Mineralocorticoid Receptor Signaling in Cardiomyocytes: From Cultured Cells to Mouse Heart. Endocrinology, 2010, 151, 4467-4476.	2.8	50
129	The neuroretina is a novel mineralocorticoid target: aldosterone upâ€regulates ion and water channels in MÃ¼ller glial cells. FASEB Journal, 2010, 24, 3405-3415.	0.5	129
130	Cnksr3 is a direct mineralocorticoid receptor target gene and plays a key role in the regulation of the epithelial sodium channel. FASEB Journal, 2009, 23, 3936-3946.	0.5	53
131	Conditional Transgenic Mice for Studying the Role of the Glucocorticoid Receptor in the Renal Collecting Duct. Endocrinology, 2009, 150, 2202-2210.	2.8	28
132	Mineralocorticoid Modulation of Cardiac Ryanodine Receptor Activity Is Associated With Downregulation of FK506-Binding Proteins. Circulation, 2009, 119, 2179-2187.	1.6	88
133	Molecular Consequences of a Frameshifted DLX3 Mutant Leading to Tricho-Dento-Osseous Syndrome. Journal of Biological Chemistry, 2008, 283, 20198-20208.	3.4	39
134	Conditional FKBP12.6 Overexpression in Mouse Cardiac Myocytes Prevents Triggered Ventricular Tachycardia Through Specific Alterations in Excitation- Contraction Coupling. Circulation, 2008, 117, 1778-1786.	1.6	57
135	Cardiomyocyte Overexpression of Neuronal Nitric Oxide Synthase Delays Transition Toward Heart Failure in Response to Pressure Overload by Preserving Calcium Cycling. Circulation, 2008, 117, 3187-3198.	1.6	73
136	Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling. Hypertension, 2008, 52, 1060-1067.	2.7	75
137	Conditional glucocorticoid receptor expression in the heart induces atrioâ€ventricular block. FASEB Journal, 2007, 21, 3133-3141.	0.5	53
138	Conditional Fkbp12.6 overexpression in mouse cardiac myocytes protects from triggered ventricular arrhythmia. Journal of Molecular and Cellular Cardiology, 2007, 42, S3-S4.	1.9	0
139	Targeted Skin Overexpression of the Mineralocorticoid Receptor in Mice Causes Epidermal Atrophy, Premature Skin Barrier Formation, Eye Abnormalities, and Alopecia. American Journal of Pathology, 2007, 171, 846-860.	3.8	69
140	A direct relationship between plasma aldosterone and cardiac L-type Ca2+current in mice. Journal of Physiology, 2005, 569, 153-162.	2.9	58
141	Conditional Mineralocorticoid Receptor Expression in the Heart Leads to Life-Threatening Arrhythmias. Circulation, 2005, 111, 3025-3033.	1.6	240
142	Development of a targeted transgenesis strategy in highly differentiated cells: a powerful tool for functional genomic analysis. Journal of Biotechnology, 2005, 116, 145-151.	3.8	7
143	Conditional gene expression in renal collecting duct epithelial cells: use of the inducible Cre-lox system. American Journal of Physiology - Renal Physiology, 2004, 286, F180-F187.	2.7	17
144	Early nongenomic events in aldosterone action in renal collecting duct cells: PKCalpha activation, mineralocorticoid receptor phosphorylation, and cross-talk with the genomic response. Journal of the American Society of Nephrology: JASN, 2004, 15, 1145-60.	6.1	67

#	Article	IF	Citations
145	Pathophysiological role of the mineralocorticoid receptor in heart: analysis of conditional transgenic models. Pflugers Archiv European Journal of Physiology, 2003, 445, 477-481.	2.8	6
146	Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 7160-7165.	7.1	93
147	Characterization of Rat NDRG2 (N-Myc Downstream Regulated Gene 2), a Novel Early Mineralocorticoid-specific Induced Gene. Journal of Biological Chemistry, 2002, 277, 31506-31515.	3.4	131
148	Tetracycline-inducible gene expression in cultured rat renal CD cells and in intact CD from transgenic mice. American Journal of Physiology - Renal Physiology, 2001, 281, F1164-F1172.	2.7	9
149	Inducible Gene Expression and Gene Modification in Transgenic Mice. Journal of the American Society of Nephrology: JASN, 2000, 11, S95-S100.	6.1	68
150	In Vivo, Villin Is Required for Ca2+-Dependent F-Actin Disruption in Intestinal Brush Borders. Journal of Cell Biology, 1999, 146, 819-830.	5.2	139
151	Regulatory Sequences of the Mouse Villin Gene That Efficiently Drive Transgenic Expression in Immature and Differentiated Epithelial Cells of Small and Large Intestines. Journal of Biological Chemistry, 1999, 274, 6476-6482.	3.4	128
152	Role of Î²-Subunit Domains in the Assembly, Stable Expression, Intracellular Routing, and Functional Properties of Na,K-ATPase. Journal of Biological Chemistry, 1998, 273, 30826-30835.	3.4	131
153	Transgenic Models in Renal Tubular Physiology. Nephron Experimental Nephrology, 1998, 6, 438-446.	2.2	9
154	Does the colonic H,K-ATPase also act as an Na,K-ATPase?. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 6516-6520.	7.1	76
155	Modulation of the Na,K-pump function by beta subunit isoforms.. Journal of General Physiology, 1994, 103, 605-623.	1.9	128
156	Chapter 4 Structureâ€"Function Relationship of Na,K-ATPase: The Digitalis Receptor. Current Topics in Membranes, 1994, 41, 71-85.	0.9	6
157	Mechanisms of urinary K+ and H+ excretion: primary structure and functional expression of a novel H,K-ATPase.. Journal of Cell Biology, 1993, 123, 1421-1429.	5.2	77
158	Role of the transmembrane and extracytoplasmic domain of beta subunits in subunit assembly, intracellular transport, and functional expression of Na,K-pumps.. Journal of Cell Biology, 1993, 123, 1751-1759.	5.2	79
159	Aldosterone/Mineralocorticoid Receptor Downstream Targets as Novel Therapeutic Targets to Prevent Cardiovascular Remodeling. , 0, , .		2
160	Potential Benefit of Mineralocorticoid Receptor Antagonists in Kidney Diseases. , 0, , .		0